AABB's donor hemovigilance efforts focus primarily on education, collaboration with other international organizations, and projects undertaken by the AABB Donor Hemovigilance Working Group.
Donor Severity Validation Study
In January 2018, a sub-group of the AABB Donor Hemovigilance Working Group undertook the task of developing the
Donor Adverse Reaction Severity Grading Tool to enhance objective assignment of severity. The severity assignment tool is designed to be used with the
Standard for Surveillance of Complications Related to Blood Donation by ISBT/AABB/IHN. The tool aims to avoid terms such as mild, moderate and severe that could set a blood collector up for legal action if a donor has an adverse event that is considered "severe." It is patterned after an established clinical severity scale, Common Terminology Criteria for Adverse Events (CTCAE1) v 5.0, which rates severity by Grades 1-5 with 1 through 5 being roughly associated with mild, moderate, severe, life-threatening and death.
A validation study to assess the validity of the proposed blood donor adverse event grading tool for hemovigilance surveillance purposes was completed in February 2019. Participants were asked to classify the severity grading of 32 donor adverse reaction case reports provided in the study utilizing the 2014
Standard for Surveillance of Complications Related to Blood Donation together with the associated
Donor Adverse Reaction Severity Grading Tool. Results of the validation study will be published in late 2019.
AABB Donor Hemovigilance Reports
Hemovigilance@aabb.org or +1.301.215.6588.